Key positives include a dramatic recent step-up in revenue, a swing from heavy operating losses to positive operating income, and strong improvement in gross margins. The company has built a sizeable and growing asset base, improved its liquidity position, and established a differentiated market position as a pure-play, vertically integrated biosimilar specialist. Its technology platform, state-of-the-art manufacturing facility, and broad pipeline of high-value biosimilars, combined with global commercialization partnerships, provide multiple avenues for future growth.

Major risks center on financial sustainability and operational execution. Net income remains deeply negative, free cash flow is strongly negative, and the balance sheet carries rising debt and negative equity, indicating a leveraged and fragile capital structure. Continued reliance on external financing exposes the company to market and credit conditions. On the business side, Alvotech faces intense competition, regulatory and manufacturing risks, potential approval delays, and persistent price pressure in the biosimilar market. Any setbacks in its pipeline, quality systems, or partner relationships could have outsized financial impact given the current leverage and cash burn.

Looking ahead, the fundamental business trajectory appears promising: revenue is scaling, the product portfolio is broadening, and operating metrics are improving as the company moves deeper into commercialization. If Alvotech can maintain product quality, secure timely approvals, and continue to grow its biosimilar franchise, its operating profile should strengthen further. However, the path to durable profitability and balance-sheet repair is not guaranteed and will likely be bumpy, with high sensitivity to regulatory outcomes, competitive dynamics, and capital-market access. Overall, the outlook combines strong strategic positioning and growth potential with elevated financial and execution risk.